Toggle navigation
Home
Search
Services
Blog
Contact
About
Cardiovascular Molecular Prognostic Kits
Bentley, Kevin L.
Genaissance Pharmaceuticals, Inc., New Haven, CT, United States
Search 4 grants from Kevin Bentley
Search grants from Genaissance Pharmaceuticals, Inc.
Share this grant:
:
:
Abstract
Funding
Institution
Related projects
Comments
Recent in Grantomics:
Massachusetts Institute of Technology
vs. funders. Who wins?
Read more...
How should you pick the next fundable research topic?
Read more...
Recently viewed grants:
Development of an Epigenetic Biomarker for Prediction of Fetal Alcohol Spectrum Disorders
Prediction of Protein Function at the Industrial Scale
Early Intervention/Chronic Obstructive Pulmonary Disease
Seventh Special Report to the US Congress ON
Role of Human Bone Matrix Factors of Articular Cartilage
Recently added grants:
Context-Dependent Effects of PARP Inhibitors on Breast Cancer Bone Metastasis
SAMHD1-mediated regulation of HIV-1 innate immunity and viral gene expression
HIV Vaccine Trials Network Laboratory Center
IMPAACT Leadership Group
SDMC - IMPAACT Leadership Group
Abstract
Funding Agency
Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Small Business Innovation Research Grants (SBIR) - Phase II (R44)
Project #
5R44HL059114-03
Application #
2750644
Study Section
Special Emphasis Panel (ZRG2-SSS-Y (15))
Project Start
1997-08-29
Project End
1999-07-31
Budget Start
1998-09-10
Budget End
1999-07-31
Support Year
3
Fiscal Year
1998
Total Cost
Indirect Cost
Institution
Name
Genaissance Pharmaceuticals, Inc.
Department
Type
DUNS #
City
New Haven
State
CT
Country
United States
Zip Code
06511
Related projects
NIH 1998
R44 HL
Cardiovascular Molecular Prognostic Kits
Bentley, Kevin L. / Genaissance Pharmaceuticals, Inc.
NIH 1997
R44 HL
Cardiovascular Molecular Prognostic Kits
Bentley, Kevin L. / Genaissance Pharmaceuticals, Inc.
Comments
Be the first to comment on Kevin Bentley's grant